In particular, reviewer #1 feels that AKT phosphorylation and mTOR levels should be investigated and suggests the use of 3D tomography to visualize the extent of the defects. Importantly, reviewer #3 points out that slowing of conduction velocity should be further investigated.
Thank you for the submission of your manuscript "Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy" to EMBO Molecular Medicine. We have now heard back from the three referees whom we asked to evaluate your manuscript. You will see that they find the topic of your manuscript potentially interesting. However, they also raise significant concerns on the study, which should be addressed in a major revision of the manuscript.
In particular, reviewer #1 feels that AKT phosphorylation and mTOR levels should be investigated and suggests the use of 3D tomography to visualize the extent of the defects. Importantly, reviewer #3 points out that slowing of conduction velocity should be further investigated.
Given the balance of these evaluations, we feel that we can consider a revision of your manuscript if you can convincingly address the issues that have been raised within the space and time constraints outlined below.
Revised manuscripts should be submitted within three months of a request for revision. They will otherwise be treated as new submissions, unless arranged differently with the editor.
I look forward to seeing a revised form of your manuscript as soon as possible.
Yours sincerely, Editor EMBO Molecular Medicine ***** Reviewer's comments ***** Referee #1:
This manuscript by Goebbels et al. titled "Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy" investigates the impact of PTEN genetic deletion on large myelinating Schwann cells in mice. Actually the mouse model used in this work was previously described in a paper published last year in Journal of Neurosciences. In this previous paper, the authors showed that PTEN deletion induced the hypermyelination of small fibers (axon diameter <2 mm) and the ectopic myelination of Remak bundles but no pathology-related defects in these small fibers. In the present manuscript, the authors show that PTEN deletion in larger cells (axon diameter > 2mm) induces a strong focal hypermyelination that translates in the formation of myelin outfoldings and tomacula. These tomacula are very similar to the tomacula observed in patients suffering of some Charcot-Marie-Tooth diseases. As observed in these patients, PTEN deleted mice showed a clear reduction of the nerve conduction velocity suggesting that these mice can be considered as a model for these human "tomacula" diseases. Tomacula appear in non-compact myelin areas where the compact myelin is supposed to be synthetized. These areas host proteins known to interact with PTEN (Dlg1 and Par3) but PTEN deletion did not affect the expression or the distribution of these proteins. However PTEN deletion increased P-AKT levels in these areas. As AKT activity is known to regulate mTOR activity, the authors investigated the role of this enzyme in the formation of tomacula using rapamycin, a specific inhibitor of mTOR activity. They show that rapamycin very significantly reduces the amount of tomacula in the PTEN deleted mice, suggesting that this drug can potentially be effective to reduce tomacula in CMT patients.
This work addresses the important question of the origin of tomacula in CMT diseases. The results are well presented and overall convincing. The conclusions presented here represent a significant step forward and notably in the direction of an effective treatment for some CMT diseases. It is a bit confusing that the story was split in two parts _ small cells VS large cells_ published separately but this does not alter the interest of the present manuscript. It may actually clarify the pathology-related findings and make them more accessible to a larger audience.
Minor revisions:
1-I have problem with the following sentence: "Extrapolating the cross-sectional findings to the known length of sciatic nerve internodes, most likely all larger caliber axons are affected."(page 5). First, this is inexact as PTEN deletion does not affect axons but myelinating Schwann cells. Second, how do you know the length of internodes of larger caliber fibers? (internodal length varies considerably; even the mean length varies considerably depending of the age; how do you get a mean length of larger caliber fibers?). So it appears necessary here to explain how you extrapolate.
2-I really appreciated the description of the different outfoldings and tomacula. It would be nice, if possible, to use 3D tomography in order to get a complete overview of the defects along the fibers.
3-I am disappointed to not see a WB analysis of P-AKT/AKT and mTOR levels in PTEN deleted nerves VS control. It would strengthen the manuscript.
4-On page 8 the statement "Because of mTOR-dependent hypertrophy of PTEN-deficient glial cells,.. " is a bit premature as only the inhibition of mTOR activity by rapamycin and the reduction of the hypertrophy, results presented later, can validate it.
5-Can you discuss about the finding that rapamycin is not affecting the density of myelinated axons and the myelin profile? Indeed as mTOR is involved in myelination, the inhibition of its activity with rapamycin is expected to reduce myelination (thinner myelin sheath and eventually more compacted axons). This is an excellent study done by an excellent research group. The only concern is its novelty. At this point this group and several others have established quite effectively the impact of the PTEN/PI3 kinase system on CNS and PNS myelination. The technical details here provide valuable information for the myelin specialist. How broad the interest in that will be is unclear.
Referee #2 (Other Remarks):
This study by Goebbels et al. focuses on the impact of genetic deletion of PTEN in the Schwann cell. This is a carefully done study by an outstanding research group, which shows that conditional deletion of PTEN in Schwann cells leads to increased activity of the PI3 Kinase/Akt pathway and excessive myelin membrane growth. This group first reported on this animal in a paper in the Journal of Neuroscience in 2010, where the focus was on increased CNS myelination, although they showed the presence of increased phospho-Akt expression in PNS myelin in that study. This is a more extensive analysis of the PNS phenotype, which in that study focused on the production of myelin by Remak Schwann cells. It provides important insight into the source of the extra myelin, which they propose emanates from the non-compacted regions of myelin. It shows that this form of dysmyelination leads to reduced peripheral nerve conduction and that the increased myelin production is mediated through mTOR. This study is consistent with the report last year of the impact of Dlg1 in Schwann cells (Cotter et al.) , which showed that increases in Dlg1 expression in Schwann cells during myelination stabilize PTEN levels. When appropriate amounts of myelin have been generated, PTEN reaches a level that suppresses Akt activity, stopping myelin production. Consistent with that study, when this group deleted PTEN in the adult, they started to have excess myelin in the Schwann cells.
Overall, this is a carefully done analysis of the impact of PTEN in myelinating Schwann cells. The specifics of these analyses provide useful new information, particularly for those investigating myelin structure, although the fundamental observation of the regulation of CNS and PNS myelination by a balance of PI3-kinase/PTEN regulation has now been demonstrated by several laboratories, including this group.
Referee #3:
The authors describe the neurophysiological, neuropathological and molecular features of a mouse model carrying a disruption of Pten in Schwann cells. PTEN is a tumor suppressor gene spontaneously mutated in many human sporadic cancers and in some hereditary cancer syndromes. Tissue-specific Pten mutations lead to tumorigenesis in the specific tissues/organs. It is already known that silencing Pten in Schwannn cells induces thickening of the myelin sheath in sciatic nerves. However, it was still unclear whether this thickening of peripheral myelin was diffuse or focal. The present manuscript unequivocally demonstrates that Schwann cell-specific mouse mutants of PTEN show focal thickenings of the peripheral myelin sheath resembling tomacula or myelin outfoldings. The neurophysiological study shows diffuse slowing of conduction velocity which certainly may be a marker of demyelinating neuropathes as HNPP or CMT with myelin outfoldings. However, the authors refer the reduction of CMAP amplitude as "a significant axonal conduction block". From the data they provide, the reduction of CMAP amplitude looks homogeneous with proximal and distal stimulus ( figure 5A ). On the contrary, a conduction block is characterized by a significant reduction of the CMAP amplitude after proximal stimulation with relatively preserved amplitude after distal stimulation. In fact, conduction block, at least in humans, has been variably defined as a 15% to 50% reduction in the compound muscle action potential at proximal as compared with distal sites of stimulation (http://neuromuscular.wustl.edu). Several animal models of hereditary or acquired demyelinating neuropatheis show conduction blocks which are in keeping with this definition (Shy et al. 1997; Baloh et al, 2009; Taylor and Pollard, 2003) . According the the neurophysiolgical study as it is, the authors may only state that there is loss or some atrophy of the axons in this mouse model. Following this observation, the authors should study whether these animals develop axonal damage/atrophy with increasing age, as it may be seen even in HNPP patients. This could be done by longitudinal neurophysiological studies and morphometry of sciatic nerves at different time points (in figure 2 they already report the number of tomacula and myelin outfoldings in P12 and P90 mutants). It should not be difficult to evaluate axon diameter and g-ratios at the same time points, to see whether there is attenuation of the axons with age.
Since Pten is a tumor suppressor gene, it would be also interesting to know whether the KO model present tumors of the Schwann cells (I did not find in the literature any data regarding this issue). As a final minor remark, there are a few typing errors in the text. Thank you for the submission of your revised manuscript "Genetic disruption of Pten in a novel mouse model of tomaculous neuropathy" to EMBO Molecular Medicine. We have now received the report from the reviewer who was asked to re-review your manuscript.
You will be glad to see that the reviewer is supportive and we can proceed with official acceptance of your manuscript pending the minor changes detailed below:
-Please see below for information regarding EMBO Molecular Medicine guidelines for statistical analysis of data. Please mention the actual p value in each case. Statistical analysis:
The description of all reported data that includes statistical testing must state the name of the statistical test used to generate error bars and P values, the number (n) of independent experiments underlying each data point (not replicate measures of one sample), and the actual P value for each test (not merely 'significant' or 'P < 0.05').
-Please adjust the format of The Paper Explained according to our journal style. You can find examples in previously published EMBO Molecular Medicine papers.
-In addition, we noted that your point-by-point response contains a figure. Since this would be published in the Review Process File, please let us know whether you agree with its publication, if you would like to delete the figure or whether you would like to opt out (more information below).
I look forward to seeing a revised version of your manuscript as soon as possible.
Yours sincerely, Editor EMBO Molecular Medicine ***** Reviewer's comments ***** Referee #3:
I think that the authors convincingly addressed the remarks I raised to the manuscript. I again congratulate with them for the interesting results of this research.
